证券代码：002901 证券简称：大博医疗 公告编号：2026-007 大博医疗科技股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2026 年 2 月 2 日上 午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 ②通过深圳证券交易所互联网投票系统投票的开始时间为 2026 年 2 月 2 日 上午 9:15 至下午 15:00 期间的任意时间。 1 1、本次股东会未出现否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议的召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2026 年 2 月 2 日（星期一）下午 14:30 2、会议召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 3、会议召集人：公司董事会 4、会议主持人：公司董事长林志雄先生主持会议。 5、现场会议地点： 厦门市海沧区山边洪东路 18 号公司会议室 本次 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-28 | 51.22 -1.31% | | -423.06万 | -2.10% | 568.46万 | 2.82% | -145.40万 | -0.72% | | 2026-01-27 | 51.90 7.45% | | 1299.83万 | 3.51% | -987.92万 | -2.67% | -311.91万 | -0.84% | | 2026-01-26 | 48.30 -3.69% | | -181.70万 | -1.25% | 1052.12万 | 7.26% | -870.43万 | -6.00% | | 2026-01-23 | 50.15 | 1.48% | -169.77万 | -1.67% | -481.25万 | -4.73% | 651.02万 | 6.40% | | 2026-01-22 49.42 -1.06% | | | -19 ...

证券之星消息，截至2026年1月27日收盘，大博医疗(002901)报收于51.9元，上涨7.45%，换手率 2.51%，成交量7.24万手，成交额3.71亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业务：医用高值耗材的生产、研发与销售。 1月27日的资金流向数据方面，主力资金净流入1299.83万元，占总成交额3.51%，游资资金净流出 987.92万元，占总成交额2.67%，散户资金净流出311.91万元，占总成交额0.84%。 该股最近90天内共有1家机构给出评级，买入评级1家。 近5日资金流 ...

交易信息汇总资金流向 截至2026年1月27日收盘，大博医疗(002901)报收于51.9元，上涨7.45%，换手率2.51%，成交量7.24万 手，成交额3.71亿元。 当日关注点 大博医疗科技股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为58,000万元至 61,000万元，同比增长62.55%至70.96%；扣除非经常性损益后的净利润为45,500万元至48,500万元，同 比增长59.42%至69.93%。基本每股收益为1.43元/股至1.50元/股。业绩增长主要得益于公司聚焦主业、 推进产品创新和国际化战略。该数据为财务部门初步测算结果，未经审计，最终以2025年年度报告为 准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月27日主力资金净流入1299.83万元，呈现明显吸筹迹象。 来自公司公告汇总：大博医疗预计2025年净利润同比增长62.55%至70.96%，业绩大幅预增。 1月27日主力资金净流入1299.83万元；游资资金净流出987.92万元；散户资金净流出311 ...

Market Performance - The pharmaceutical sector increased by +0.29% on January 26, 2025, outperforming the CSI 300 index by 0.19 percentage points, ranking 8th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, vaccines (+7.99%), in vitro diagnostics (+3.73%), and blood products (+3.47%) showed the best performance, while hospitals (-2.01%), medical R&D outsourcing (-1.36%), and offline pharmacies (-1.18%) lagged behind [1] - Top three individual stock gainers were Maike Biological (+20.03%), Cap Bio (+20.03%), and Zhijiang Biological (+20.01%), while the biggest losers were Weikang Pharmaceutical (-8.50%), Medisi (-7.28%), and Meinian Health (-6.08%) [1] Industry News - Recently, InSilico Medicine announced that its self-developed oral NLRP3 inhibitor ISM8969 has received IND approval from the FDA for the treatment of Parkinson's disease [2] - The upcoming Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetic characteristics of ISM8969 in healthy volunteers, aiming to determine the recommended dosage for subsequent studies [2] - ISM8969 is an innovative NLRP3 inhibitor with ideal blood-brain barrier penetration characteristics, targeting pathological inflammatory responses to support neuronal survival and function in neurodegenerative disease patients [2] - The drug candidate was discovered and optimized using InSilico Medicine's AI platform, Chemistry42 [2] Company News - Jiuan Medical (002432) expects to achieve a net profit attributable to shareholders of 2.02-2.35 billion yuan in 2025, representing a year-on-year growth of 21.05%-40.83%, with a non-recurring net profit forecast of 2.07-2.40 billion yuan, up 23.18%-42.81% [3] - Sanofi Guojian (688336) anticipates a revenue of 4.20 billion yuan in 2025, a significant year-on-year increase of 251.76%, with a net profit of 2.90 billion yuan, up 311.35%, and a non-recurring net profit of 2.80 billion yuan, reflecting a staggering growth of 1038.21% [3] - Dabo Medical (002901) forecasts a net profit of 580-610 million yuan in 2025, a growth of 62.55%-70.96%, with a non-recurring net profit of 455-485 million yuan, up 59.42%-69.93% [3] - Microchip Biotech (688321) expects a revenue of 910 million yuan in 2025, a year-on-year increase of 38.32%, with a net profit of 53 million yuan, marking a return to profitability, and a non-recurring net profit of 38 million yuan, also indicating a return to profitability compared to the previous year [3]

公告中提到，2025年度的基本每股收益预计为1.43元/股至1.5元/股，相较于上年同期的0.86元/股也有明 显增长。 公司表示，业绩增长的原因主要归功于聚焦主业、坚持产品创新、技术服务及国际化发展战略，从而推 动各项业务的持续稳定健康发展。 （大博医疗公告） 近日，大博医疗发布公告称，预计2025年度归母净利润约为5.8亿元至6.1亿元，同比增长约62.55%至 70.96%。上年同期的归母净利润为3.57亿元，显示出公司在业绩上的显著提升。 ...

Core Viewpoint - The understanding of "growth" in the orthopedic high-value consumables industry is shifting towards maintaining profit and cash flow under continuous price pressure, rather than just revenue expansion [2]. Group 1: Performance Forecast - Dabo Medical expects a net profit attributable to shareholders of 580-610 million yuan for 2025, representing a year-on-year growth of 62.55%-70.96% [2][3]. - The net profit after deducting non-recurring gains and losses is projected to be 455-485 million yuan, with a year-on-year increase of 59.42%-69.93% [2][3]. - The basic earnings per share are estimated to be between 1.43 and 1.50 yuan, compared to 0.86 yuan in the previous year [3]. Group 2: Consistent Performance - The performance in 2025 is not a result of year-end rush but rather a gradual realization throughout the year [4][6]. - In the first three quarters, the company achieved a net profit of 425 million yuan, a year-on-year increase of 77.03%, laying a solid foundation for the annual performance forecast [4]. Group 3: Profit Growth vs. Revenue Growth - The company's revenue growth of 22.69% in the first three quarters is not particularly outstanding, but profit growth significantly outpaces revenue growth [7][8]. - The increase in operating profit and net profit attributable to shareholders is notably higher than revenue growth, indicating improved operational efficiency and cost control [8]. Group 4: Profit Structure and Cash Flow - The projected growth in net profit after deducting non-recurring items aligns closely with the overall net profit growth, suggesting that the profit increase is primarily driven by core business improvements rather than one-off items [9]. - The net cash flow from operating activities reached 468 million yuan in the first three quarters, significantly exceeding the profit growth rate [10][11]. Group 5: Structural Realization in a Normalized Environment - The performance forecast for 2025 reflects a structural realization, characterized by profit growth outpacing revenue growth and simultaneous improvement in net profit and cash flow [12]. - This indicates that the company has adapted to the normalized procurement environment and completed internal adjustments [12]. Group 6: Changing Growth Dynamics - The noteworthy aspect of the performance forecast is the change in growth dynamics, emphasizing profit elasticity, cash flow improvement, and gradual adaptation of the operational structure to the new environment [14].

Group 1 - The core viewpoint of the news highlights the performance of the China Medical and Medical Device Innovation Index, with notable stock movements, including a leading increase of 8.29% by Sangfor Technologies [1] - The Medical Innovation ETF has seen continuous net inflows over the past week, with a maximum single-day net inflow of 40.537 million yuan, totaling 114 million yuan [1] - A significant research breakthrough was reported regarding the oral nucleoside drug VV116, which shows promising antiviral activity against the Nipah virus, providing a potential treatment option for high-risk populations [1] Group 2 - Guosen Securities noted that the innovative drug sector exhibited significant excess returns in 2025, driven by international business development, continuous positive clinical data, and supportive policies [2] - The Medical Innovation ETF closely tracks the China Medical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies to reflect the overall performance of the sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Heng Rui Medicine, and Mindray Medical, collectively accounting for 63.75% of the index [2]

截至2026年1月26日收盘，大博医疗(002901)报收于48.3元，下跌3.69%，换手率1.03%，成交量2.98万 手，成交额1.45亿元。 2025年度业绩预告 大博医疗科技股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为58,000万元至 61,000万元，同比增长62.55%至70.96%；扣除非经常性损益后的净利润为45,500万元至48,500万元，同 比增长59.42%至69.93%。基本每股收益为1.43元/股至1.50元/股。业绩增长主要得益于公司聚焦主业、 推进产品创新和国际化战略。该数据为财务部门初步测算结果，未经审计，最终以2025年年度报告为 准。 业绩预告 大博医疗发布业绩预告，预计2025年全年归属净利润盈利5.8亿元至6.1亿元。大博医疗发布业绩预告， 预计2025年全年扣非后净利润盈利4.55亿元至4.85亿元。大博医疗发布业绩预告，预计2025年全年每股 收益盈利1.43元至1.5元。 公司公告汇总 当日关注点 交易信息汇总 资金流向 1月26日主力资金净流出181.7万元；游资资金净流入1052.12万元；散户资金净流出870.43万元。 业绩 ...

近日，大博医疗科技股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为58,000 万元至61,000万元，同比增长62.55%至70.96%；扣除非经常性损益后的净利润为45,500万元至48,500万 元，同比增长59.42%至69.93%。基本每股收益为1.43元/股至1.50元/股。业绩增长主要得益于公司聚焦 主业、推进产品创新和国际化战略。该数据为财务部门初步测算结果，未经审计，最终以2025年年度报 告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月26日收盘，大博医疗（002901）报收于48.3元，较前一交易日下跌3.69%，最新总市值为 199.97亿元。该股当日开盘50.15元，最高50.15元，最低48.26元，成交额达1.45亿元，换手率为1.03%。 《2025年度业绩预告》 最新公告列表 ...